NCT06059261 2026-02-18
Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.
Chongqing University Cancer Hospital
Phase 2 Recruiting
Clinical Trials
9 trialsNCT07327411 2026-01-08
Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors
Second Affiliated Hospital of Soochow University
Phase 2 Not yet recruiting
NCT05959356 2025-12-17
CEIL
Sun Yat-sen University
Phase 2 Recruiting
NCT07159191 2025-09-08
Envafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
Peking Union Medical College Hospital
Phase 2 Not yet recruiting
NCT07142863 2025-08-27
Envafolimab Combined With Neoadjuvant Chemotherapy Treat Stage IIb Resectable Osteosarcoma Patients
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2 Not yet recruiting
NCT06772233 2025-07-31
A Study of Regorafenib Combined With Envafolimab for Metastatic Gastrointestinal Stromal Tumors With Kit Gene Exon 17 Mutation That Failed Standard Treatment
Peking University
Phase 2 Not yet recruiting
NCT07003815 2025-06-04
Envafolimab With Chemotherapy and Simvastatin in Advanced Biliary Tract Cancer
Tongji Hospital
Phase 2 Not yet recruiting
NCT05112991 2025-05-29
Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer
3D Medicines
Phase 2 Recruiting
NCT05941325 2025-05-18
A Single-arm, Open-label, Single-center Prospective Study of Fruquintinib Combined With Envafolimab in the Treatment of Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma
Shanghai 6th People's Hospital
Phase 2 Recruiting